Partnership Opportunites

Partner With Us

With huge investments being made to address the critical unmet need to develop retinal disorder treatments, ophthalmic drug developers are seeking more sophisticated imaging tools and AI-powered technologies to provide faster, less-invasive indications of disease progression and drug efficacy.

The Retinal Imaging Biomarkers & Endpoints Summit attracted key decision makers from leading ophthalmology-focused biopharma, keen to learn more about cutting-edge technologies and solutions available to transform their preclinical and clinical pipelines. Join this meeting to explore your unique opportunity to establish long-term partnerships and demonstrate your technical expertise and abilities to enhance retinal imaging biomarker development.

Why Partner?

Showcase your expertise to our audience of highly engaged stakeholders with opportunities to present and demonstrate how your solutions can elevate retinal drug trials

Network one-to-one with key decision makers to understand their requirements first-hand

Establish greater brand awareness among retinal drug developers seeking to invest in novel innovations to accelerate their pipeline

In 2023, Experts Needed Your Help With:

  • More sophisticated imaging modalities to enhance accuracy and objectiveness of retinal measurements
  • AI-based tools to accelerate image processing and shorten drug development timelines
  • Preclinical and clinical support to facilitate successful generation of primary and secondary image-derived endpoints

Attendees at Previous Hanson Wade Ophthalmic Events Include: